Intuitive Surgical (ISRG) Stock Drops to 52-Week Low Ahead of Earnings Thursday

TLDR

• ISRG fell 6.28% to a fresh 52-week low as investors sold ahead of the July 16 earnings report
• TD Cowen cut its price target from $585 to $520, citing competition and valuation concerns
• Stifel reiterated a Buy rating and $670 price target after surveying 100 robotic surgeons
• Options data suggests the market is pricing in a potential 7% move on earnings
• ISRG is down 28.12% year-to-date, with a current market cap of $144.1 billion

---

Intuitive Surgical stock hit a new 52-week low on Monday, dropping 6.28% as investors moved to the sidelines before the company’s July 16 earnings release. The stock now carries a year-to-date decline of 28.12%.

Intuitive Surgical, Inc., ISRG

The selloff came as TD Cowen trimmed its price target on ISRG from $585 to $520, keeping a Buy rating but flagging concerns about rising competition and the stock’s valuation. That move weighed on sentiment and helped push the stock to its lowest point in the past year.

Stifel offered a contrasting view, reiterating a Buy rating and a $670 price target. The firm surveyed 100 practicing robotic surgeons across multiple specialties to gauge how a more competitive robotic surgery market could affect Intuitive’s position.

Survey responses came back broadly positive for the company. Surgeons viewed recent updates to the da Vinci 5 system as helping differentiate Intuitive’s offering from newer entrants.

Competitive Pressure Builds

The U.S. robotic surgery market is going through its first major competitive shift in more than 20 years. Intuitive, which has operated in a near-monopoly environment for most of that period, is now facing new challengers.

Despite that, surgeons in the Stifel survey pointed to system price and instrument costs as the main barriers to wider robotic surgery adoption, rather than preference for competing platforms.

Piper Sandler also weighed in, reiterating an Overweight rating with a $580 price target, backed by positive feedback from a large U.S. healthcare system on Intuitive’s da Vinci platform.

Taylor Patton was promoted to Chief Commercial and Marketing Officer, effective July 1, as part of a leadership transition at the company.

What to Watch on Earnings Day

Options pricing ahead of the July 16 report suggests traders are expecting a move of around 7% in either direction when results drop.

ISRG trades at a price-to-earnings ratio of 49.7, which remains elevated even after the year-to-date pullback. The company holds a gross profit margin of 66%, reflecting the strength of its recurring revenue model tied to procedures and consumables.

Key areas of focus for the earnings call are likely to include procedure volume growth, progress in markets outside the U.S., and any updates on how tariffs and cost pressures are affecting margins.

China has been flagged as a headwind, along with shifting medical trends that could reduce certain surgery volumes.

Da Vinci 5 updates, including enhancements to Intuitive Telepresence and extended instrument use, became available in the U.S. in June. Global rollout remains subject to regulatory approvals.

InvestingPro analysis lists ISRG among its Most Undervalued opportunities based on its Fair Value model.

TD Cowen’s revised price target of $520 currently sits below where several other analysts have set their bar, making Wednesday’s report a key test for the stock’s near-term direction.